The revised Bethesda guidelines: Extent of utilization in a university hospital medical center with a cancer genetics program

Hereditary Cancer in Clinical Practice

Volumn 8, Issue 1, 2010, Pages

  Mukherjee, Aparna ^a   McGarrity, Thomas J ^a   Ruggiero, Francesca ^a   Koltun, Walter ^a   McKenna, Kevin ^a   Poritz, Lisa ^a   Baker, Maria J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER REGISTRY; CANCER RISK; DATA BASE; ELECTRONIC MEDICAL RECORD; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

EID: 79551551461     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-8-9     Document Type: Article

References (46)

1. Terdiman JP, Gum JR, Conrad PG, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001, 120:21-30. 10.1053/gast.2001.20874, 11208710.
2. Lynch HT, Jass J, Lynch JF, et al. Hereditary colorectal cancer: an updated review. Part II: The Lynch syndrome (hereditary nonpolyposis colorectal cancer). Gastroenterology and Hepatology 2005, 1:117-27.
3. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999, 36:801-818. 1734258, 10544223.
4. Lynch HT, de la Chapelle A. Genomic medicine-hereditary colorectal cancer. N Engl J Med 2003, 348:919-32. 10.1056/NEJMra012242, 12621137.
5. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129:415-21.
6. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-56. 10.1016/S0016-5085(99)70510-X, 10348829.
7. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997, 113:1146-58. 10.1053/gast.1997.v113.pm9322509, 9322509.
8. Aaltonen LA, Pelomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812-816. 10.1126/science.8484121, 8484121.
9. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer Res 1993, 53:5853-55.
10. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-57.
11. Gologan A, Krasinskas A, Hunt J, et al. Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability. Arch Pathol Lab Med 2005, 129:1390-97.
12. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology 2006, 130:577-87. 10.1053/j.gastro.2006.01.031, 16472609.
13. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-8. 10.1093/jnci/djh034, 2933058, 14970275.
14. Burgart LJ. Testing for defective DNA mismatch repair in colorectal carcinoma. Arch Pathol Lab Med 2005, 129:1385-89.
15. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-25. 10.1007/BF02053699, 2022152.
16. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89:1758-62. 10.1093/jnci/89.23.1758, 9392616.
17. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis. JAMA 2005, 293:1986-94. 10.1001/jama.293.16.1986, 15855432.
18. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary nonpolyposis colorectal cancer-associated mutations in MSH2 and MLH1. J Med Genet 2000, 37:641-5. 10.1136/jmg.37.9.641, 1734690, 10978352.
19. Rodriguez-Moranta F, Castells A, Andreu M, et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol 2006, 101:1104-11. 10.1111/j.1572-0241.2006.00522.x, 16696788.
20. Schmeler KM, Lynch HT, Chen L, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. New Engl J Med 2006, 354:261-9. 10.1056/NEJMoa052627, 16421367.
21. Järvinen HJ, Aarnio M, Mutonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-34. 10.1016/S0016-5085(00)70168-5, 10784581.
22. Alberto VO, Harocopos CJ, Patel AA, et al. Family and personal history in colorectal cancer patients: what are we missing?. Colorectal Disease 2006, 8:612-14. 10.1111/j.1463-1318.2006.01047.x, 16919116.
23. Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004, 2:813-19. 10.1016/S1542-3565(04)00352-0, 15354282.
24. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary non-polyposis colorectal cancer syndrome. Obst & Gynecology 2005, 105:569-574.
25. Pate v. Threlkel, 661 So2 d 278 (Fla 1995).
26. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979-85. 10.1001/jama.293.16.1979, 2933042, 15855431.
27. Mecklin J-P, Järvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 1986, 29:160-4. 10.1007/BF02555012, 3943429.
28. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 1990, 3:332-5.
29. Watson P, Lin K, Rodriguez-Bigas MA, et al. Colorectal carcinoma survival among nonpolyposis colorectal cancer family members. Cancer 1998, 83:259-66. 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L, 9669808.
30. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77. 10.1056/NEJM200001133420201, 10631274.
31. Sankila R, Anderson LA, Järvinen HJ, et al. Better survival rates in patients with MLH-1 associated hereditary colorectal cancer. Gastroenterology 1996, 110:682-7. 10.1053/gast.1996.v110.pm8608876, 8608876.
32. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23(3):609-18. 10.1200/JCO.2005.01.086, 15659508.
33. Lin KM, Shashidharan M, Ternent CA, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 1998, 41:428-33. 10.1007/BF02235755, 9559626.
34. Carethers JM. Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut 2006, 55:759-61. 10.1136/gut.2005.085274, 1856230, 16698750.
35. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006, 55:848-55. 10.1136/gut.2005.073015, 1856227, 16299036.
36. Overbeek LI, Hermens RP, vanKrieken JH, et al. Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomized controlled trial. Virchows Arch 2010, 456:653-659. 10.1007/s00428-010-0907-7, 2880231, 20379742.
37. Kievit W, de Bruin JH, Adang EM, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005, 54:97-102. 10.1136/gut.2004.039123, 1774368, 15591512.
38. Schofield L, Watson N, Grieu F, et al. Population based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009, 124:1097-1102. 10.1002/ijc.23863, 19072991.
39. Hampel H, Frankel Wendy L, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-8. 10.1200/JCO.2008.17.5950, 2645108, 18809606.
40. EGAPP Working Group Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11(1):35-41. 10.1097/GIM.0b013e31818fa2ff, 2743612, 19125126, EGAPP Working Group.
41. Faucett A. National Society of Genetic Counselors Cancer Listserv. Cited 11 Mar 2009.
42. Mvundura M, Grose SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010, 12:93-104. 10.1097/GIM.0b013e3181cd666c, 20084010.
43. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nature Genetics 2008, 41:112-117. 10.1038/ng.283, 19098912.
44. Grindedal EM. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2460-2467. 10.1158/1055-9965.EPI-09-0058, 19723918.
45. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, particularly among MSH2 mutation carriers. J Med Genet 2010, 47:464-470. 10.1136/jmg.2010.076992, 20591884.
46. Burton AM, Peterson SK, Marani SK, et al. Health and lifestyle behaviors among persons at high risk of Lynch syndrome. Cancer Causes Control 2010, 21:513-521. 10.1007/s10552-009-9482-0, 20012181.